Celularity Inc (CELU) income statement
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.48−0.09 (-15.41%)
Close on Nov 18, 2026Market cap $15.68MP/E –Yield –
Celularity Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 19.2%
- Operating margin
- -264.3%
- Net margin
- -245.7%
- Return on equity, FY2025
- 627.7%
Financial strength
- Current ratio
- 0.11
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.84
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?